236 related articles for article (PubMed ID: 12705638)
1. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results.
Roudier MP; Vesselle H; True LD; Higano CS; Ott SM; King SH; Vessella RL
Clin Exp Metastasis; 2003; 20(2):171-80. PubMed ID: 12705638
[TBL] [Abstract][Full Text] [Related]
2. Intravenous aminohydroxypropylidene bisphosphonate does not modify 99mTc-hydroxymethylene bisphosphonate bone scintigraphy. A prospective study.
Macro M; Bouvard G; Le Gangneux E; Colin T; Loyau G
Rev Rhum Engl Ed; 1995 Feb; 62(2):99-104. PubMed ID: 7600079
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Predictors of bone metastasis in pre-treatment staging of asymptomatic treatment-naïve patients with prostate cancer.
Moslehi M; Cheki M; Salehi-Marzijarani M; Amuchastegui T; Gholamrezanezhad A
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):286-9. PubMed ID: 23478119
[TBL] [Abstract][Full Text] [Related]
5. Palliative treatment of bone metastases in hormone-refractory prostate cancer: effects of pamidronate on the carboxyterminal telopeptide of type-I collagen level in patients with increasing prostate-specific antigen levels.
Kawashima H; Tanaka T; Kuratsukuri K; Uchida J; Sugimura K; Tamada S; Nishisaka N; Kumata K; Iwai Y; Ikemoto S; Ezaki K; Nakatani T
Urol Int; 2007; 78(4):345-50. PubMed ID: 17495494
[TBL] [Abstract][Full Text] [Related]
6. Preserved value of bone scintigraphy for the detection of skeletal metastases in prostate cancer patients with low prostate-specific antigen levels: effect of hormonal therapy and poor histologic differentiation.
Caglar M; Tuncel M
Clin Nucl Med; 2002 Jul; 27(7):532-3. PubMed ID: 12072787
[No Abstract] [Full Text] [Related]
7. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
8. 99mTc-antigranulocyte bone marrow scintigraphy of breast and prostate skeletal metastases.
Limouris GS; Voliotopoulos V; Stavraka A; Vlahos L
Anticancer Res; 1997; 17(3B):1615-8. PubMed ID: 9179204
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
10. The relationship between the serum prostate specific antigen and whole body scintigraphy in prostate cancer patients after prostatectomy.
Begic A; Kucukalic-Selimovic E; Obralic N; Duric O; Lacevic N; Begovic-Hadzimuratovic S; Skopljak A; Dzubur-Aganovic M
Med Arh; 2006; 60(1):54-5. PubMed ID: 16425536
[TBL] [Abstract][Full Text] [Related]
11. Study of the Usefulness of Bone Scan Index Calculated From 99m-Technetium- Hydroxymethylene Diphosphonate (
Higashiyama S; Yoshida A; Kawabe J
Curr Med Imaging; 2021; 17(1):89-96. PubMed ID: 32484112
[TBL] [Abstract][Full Text] [Related]
12. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
Small EJ; Smith MR; Seaman JJ; Petrone S; Kowalski MO
J Clin Oncol; 2003 Dec; 21(23):4277-84. PubMed ID: 14581438
[TBL] [Abstract][Full Text] [Related]
13. Enhanced uptake of 99Tcm-MDP in skeletal metastases from prostate cancer following initiation of hormone treatment: potential for increasing delivery of therapeutic agents.
Bushnell DL; Madsen M; Kahn D; Nathan M; Williams RD
Nucl Med Commun; 1999 Oct; 20(10):875-81. PubMed ID: 10528290
[TBL] [Abstract][Full Text] [Related]
14. Is bone scintigraphy necessary in initial staging of prostate cancer patients?
Jaukovic L; Adjinovic B; Cerovic S; Joksimovic M; Soldatovic Z
Hell J Nucl Med; 2011; 14(2):126-30. PubMed ID: 21761013
[TBL] [Abstract][Full Text] [Related]
15. [Predictive value of prostate-specific antigen and Gleason sum for results of radionuclide bone scintigraphy in patients with prostate cancer].
Wang TY; Chen XP; Li XS; Jia Yx; Cheng J; Zhang JH; Cai L; Zhang Z; Gong K; He ZS; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Aug; 44(4):528-34. PubMed ID: 22898839
[TBL] [Abstract][Full Text] [Related]
16. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
[TBL] [Abstract][Full Text] [Related]
17. Metabolic effects of single-dose pamidronate administration in prostate cancer patients with bone metastases.
Berruti A; Dogliotti L; Tucci M; Tarabuzzi R; Guercio S; Torta M; Tampellini M; Dovio A; Poggio M; Scarpa RM; Angeli A
Int J Biol Markers; 2002; 17(4):244-52. PubMed ID: 12521128
[TBL] [Abstract][Full Text] [Related]
18. 99mTc depreotide scan compared with 99mTc-MDP bone scintigraphy for the detection of bone metastases and prediction of response to hormonal treatment in patients with breast cancer.
Van Den Bossche B; D'haeninck E; De Winter F; Van Belle S; Dierckx RA; Van De Wiele C
Nucl Med Commun; 2004 Aug; 25(8):787-92. PubMed ID: 15266172
[TBL] [Abstract][Full Text] [Related]
19. [Bone scintigraphy and rhenium radioisotope management in the course of metastatic prostatic cancer].
Ostwald E; Sabri O; Cremerius U; Jakse G; Büll U
Nuklearmedizin; 1999; 38(7):302-5. PubMed ID: 10599071
[TBL] [Abstract][Full Text] [Related]
20. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Chen B;
J Natl Cancer Inst; 2002 Oct; 94(19):1458-68. PubMed ID: 12359855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]